12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Naproxcinod regulatory update

NicOx withdrew an MAA in Europe for naproxcinod to treat signs and symptoms of osteoarthritis of the knee and hip in adults. The company said EMA's CHMP indicated that the committee would not issue a positive...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >